Avastin, Herceptin, Rituxan Now Sold Under Tighter Control by Drug Maker

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

A move by Genentech has eliminated discounts and rebates hospitals receive when they purchase three of the company’s top-selling infused cancer drugs.

To access this subscriber-only content please log in or renew your subscription.

Looking for IP Login? Our IP Login system is now automatic. If your institution has a site license, please log in from on site or via your VPN to access this content.

Login Subscribe

YOU MAY BE INTERESTED IN

Login